AUTHOR INDEX

Ahdoot, M., 172
Alfandari, S., 12
Aljada, A., 20
Andreoulakis, N., 141
Augerten, A., 120

Bander, J., 69
Barrera, R., 172
Barzilay, Z., 120
Beaucaire, G., 12
Bellomo, R., 186
Ben-Abraham, R., 120
Bloch, K.E., 177
Bredle, D.L., 78
Bugedo, G., 73

Cabrera, M.E., 151
Camacho, M.T., 191
Carlet, J., 7
Castillo, L., 73
Cheval, C., 7, 107
Choisy, P., 12
Cook, D.J., 1, 199

Dandona, P., 20
DeFigueiredo, L. P., 93
De Jonghe, B., 7
Doré, P., 114
Dupont, H., 107

Evans, D.J., 93

Fauchère, J.-L., 114
Ferrand, E., 114
Fierobe, L., 107
Friedman, G., 69
Fuhrman, B.P., 20, 84
Fuller, H.D., 1

Garrouste, M., 7
Gebhard, M.-M., 99, 133
Georges, H., 12
Groeger, J.S., 172
Groeneveld, A.B.J., 34
Grollier, G., 114
Guery, B., 12
Guilley, J., 12
Gunnarsson, B., 84
Guzman, S., 73

Harel, R., 120
Hays, S., 93

Herbertson, M.J., 125
Hernan, L.J., 84
Hernandez, G., 73
Hernandez, J., 141
Hira, M., 114
Huang, Y, 172
Hultquist, K., 141
Hynninen, M., 63

Jäger, L., 29
Jacka, M.J., 198
Jakob, H., 133
Jousela, I., 63
Jugoon, S., 177

Kalhan, S.C., 151
Kellum, J.A., 186
Kim, Y.M., 186
Kolkman, J.J., 34
Kramer, G.C., 93
Kuusela, P., 63

Lagonidis, D., 164
Lancaster, J.R. Jr., 186
Lang, J.D. Jr., 93
LeCorre, F., 107
Leroy, O., 12
Leung, D., 172
Lopez, F., 73

Magder, S., 164
Maiz, A., 73
Markkanen, H., 63
Martin, E., 99, 133
Mathru, M., 93
Meade, M.O., 198
Meier-Hellmann, A., 78
Melendez, J., 172
Meuwissen, S.G.M., 34
Misset, B., 7
Moine, P., 107
Montuclard, L., 7
Moreh, O., 120
Motsch, J., 133

Nasraway, S., 69

Oberhoffer, M., 29
Ondulick, B., 186

Papo, M.C.., 20
Paret, G., 120

Peterson, J.C., 1
Piilonen, A., 63
Pinsky, M.R., 186

Raszynski, A., 141
Reinhart, K., 29, 78
Robert, R., 114
Rotta, A.T., 20, 84
Roussos, C., 39
Russell, J.A., 125

Sackner, M.A., 177
Saidel, G.M., 151
Sakka, S.G., 78
Schmidt, H., 99
Schmidt, W., 99
Schnabel, P.A., 133
Schweppenhäuser, W., 99
Secchi, A., 99
Shelly, M., 69
Sinuff, T., 1, 199
Slotman, G., 69
Steinhorn, D.M., 20, 84
Sussmane, J., 141

Takkunen, O., 63
Tanigawa, K., 186
Tenaillon, A., 69
Timsit, J.-F., 7, 107
Torbati, D., 191
Totapally, B.R., 141, 191

Vaara, M., 63
Valtonen, M., 63
Van Leuwen, P.A., 69
Vardi, A., 120
Vargas, C., 73
Vassilakopoulos, T., 39
Velasco, N., 73
Vincent, J.-L., 69
Vogelsang, H., 29

Wainstein, C., 73
Walley, K.R., 125
Weimann, J., 133
Wolfsdorf, J., 141, 191

Zakynthinos, S., 39
Zar, H., 186
Zink, W., 133

SUBJECT INDEX

Adult respiratory distress syndrome (ARDS)
  inhaled nitric oxide salvage therapy for, 107–113
  ketaconazole prophylaxis for, 1–6, 198(letter), 199(reply)
  prognostic respiratory variables, adapting for children, 120–124
Albumin, *vs.* saline, as volume challenge in post-cardiac surgery patients, 164–171
Antimicrobial therapy
  anti-anaerobic, for nosocomial pneumonia, 114–119
  with ketaconazole, for ARDS prophylaxis, 1–6, 198(letter), 199(reply)
ARDS. *See* Adult respiratory distress syndrome
Arterial oxygen-carrying capacity, hypercapnia effect on, 191–197

Bladder mucosa, P_{CO_2}, P_{O_2} and pHi for tissue perfusion monitoring, 93–98
Blood flow
  intestinal villous, during endotoxemia, 99–105
  regional, nitric oxide metabolism in sepsis and, 186–190

Calcitonin immunoreactivity, leukocyte procalcitonin content and, 29–33
Cardiac filling pressure, *vs.* intrathoracic blood volume in sepsis/septic shock, 78–83
Cardiac function, in sepsis, IL-1ra and, 69–72
Cardiopulmonary bypass surgery, postoperative volume challenge, 164–171
Cardiovascular dysfunction, weaning failure and, 45–46
Children, ARDS prognostic respiratory variables for, 120–124
Circulatory failure, early liver dysfunction and blood lactate in, 7–11
Community-acquired pneumonia mortality, HA-VAP impact on, 12–19

Dobutamine infusion, myocardial oxygen consumption during, 125–132

E-selectin, in pancreatitis vs. sepsis, 63–68
Endotoxemia
  dobutamine infusion for, myocardial oxygen consumption during, 125–132
  intestinal villous blood flow during, 99–105
Enteral nutrition, short fasting period, gut mucosal atrophy after, 73–77
Epinephrine, intestinal villous blood flow during endotoxemia and, 99–105

Fasting, gut mucosal atrophy after, 73–77
Flow triggering, with pressure support ventilation during spontaneous breathing, 172–176

Gastric feeding, effect on intragastric PCO_2 tonometry, 34–38
Gastric intramural pH, weaning failure and, 47
Gut mucosal atrophy, after short enteral fasting period, 73–77

Heart function, in sepsis, IL-1ra and, 69–72
High-frequency oscillatory ventilation, nitric oxide and nitrogen dioxide concentrations during, 141–147
Hospital-acquired ventilator-associated pneumonia, CAP mortality and, 12–19
Hypercapnia, arterial oxygen-carrying capacity and, 191–197
Hypoxemia, weaning failure and, 47

IL-1ra. *See* Interleukin 1 receptor antagonist
Inductance cardiography, for left ventricular filling monitoring, 177–185
Interleukin 1 receptor antagonist (IL-1ra)
  cardiac function in sepsis and, 69–72
  in pancreatitis vs. sepsis, 63–68
Intrathoracic blood volume, vs. cardiac filling pressure in sepsis/septic shock, 78–83
Ischemia
  lactate accumulation during, model analysis of, 151–163
  tissue perfusion monitoring, bladder mucosal P_{CO_2}, P_{O_2} and pHi for, 93–98

Katacalcin immunoreactivity, leukocyte procalcitonin content and, 29–33
Ketaconazole, for ARDS prophylaxis, 1–6, 198(letter), 199(reply)

Lactate
  accumulation during muscle ischemia, 151–163
  early hepatic dysfunction in acute circulatory failure and, 7–11
Left ventricular end-diastolic pressure, weaning failure and, 45
Left ventricular filling, inductance cardiography of, 177–185
Leukocytes, procalcitonin content in, 29–33
Liquid ventilation
  attenuation of pulmonary oxidative damage, 20–28
  partial, acute lung injury histopathology and, 84–92
Liver dysfunction, in acute circulatory failure, blood lactate and, 7–11
Lung injury, pulmonary histopathology, partial liquid ventilation and, 84–92

Mechanical ventilation
  flow triggering with pressure support ventilation during, 172–176
  hypercapnia effect on arterial oxygen-carrying capacity, 191–197
  inappropriate relationship of needs and neurorespiratory capacity, 39–45
  reduction of duration, 47–52
  weaning from. *See* Weaning
Microembolism, sustained pulmonary hypertension for, 133–140
Muscle ischemia. *See* Ischemia
Myocardial oxygen consumption, during dobutamine infusion in endotoxemia, 125–132

Nasal intermittent positive-pressure ventilation (NIPPV), 57–58
Nitric dioxide, concentration during high-frequency oscillatory ventilation, 141–147
Nitric oxide
  as ARDS salvage therapy, 107–113
  concentration during high-frequency oscillatory ventilation, 141–147
  metabolism, in canine sepsis, 186–190

Nitric oxide (*Continued*)
selective vasodilation by inhalation, during sustained pulmonary hypertension, 133–140
Norepinephrine, intestinal villous blood flow during endotoxemia and, 99–105
Nosocomial pneumonia
anti-anaerobic antimicrobial therapy for, 114–119
ventilator-associated, effect on community-acquired pneumonia mortality, 12–19

Organ failure development, weaning failure and, 46–47
Oxygen cost of breathing, weaning failure and, 46–47

Pancreatitis, IL-1ra and E-selectin levels vs. sepsis, 63–68
P_{CO_2} tonometry, intragastric, effect of gastric feeding on, 34–38
Peak inspiratory pressure (PIP), ARDS prognosis in children and, 120–124
PEEP. *See* Positive end-expiratory pressure
pHI, weaning failure and, 47
PIP (peak inspiratory pressure), ARDS prognosis in children and, 120–124
Pneumonia
community-acquired, mortality from, 12–19
hospital-acquired ventilator-associated, 12–19
nosocomial, anti-anaerobic antimicrobial therapy for, 114–119
Positive end-expiratory pressure (PEEP)
ARDS prognosis in children and, 120–124
intrinsic, counterbalance of, 53
Pressure support ventilation, with flow triggering during spontaneous breathing in intubated patients, 172–176
Procalcitonin, content in leukocytes, 29–33
Pulmonary hypertension, sustained, nitric oxide inhalation selective vasodilation by, 133–140

Reactive oxygen species, attenuation of pulmonary oxidative damage, 20–28
Regional blood flow, nitric oxide metabolism in sepsis and, 186–190
Reperfusion, bladder mucosal tissue perfusion monitoring, 93–98

Sepsis
canine, nitric oxide metabolism in, 186–190
cardiac function in, IL-1ra and, 69–72
IL-1ra and E-selectin levels *vs.* pancreatitis, 63–68
intrathoracic blood volume *vs.* cardiac filling pressures in, 78–83
Septic shock, intrathoracic blood volume *vs.* cardiac filling pressure in, 78–83
Spontaneous breathing
flow triggering with pressure support ventilation during, 172–176
initial trial of, 51–52
Stealing effect theory, weaning failure and, 46–47

Tension-time index, in weaning, 40
Thoracocardiography, for left ventricular filling monitoring, 177–185
Tissue perfusion monitoring, bladder mucosal, 93–98
Tracheal gas insufflation, for weaning, 57

Ventilation index, prognostic value in children with ARDS, 120–124
Ventilator-associated pneumonia, CAP mortality and, 12–19
Ventilatory techniques, for weaning, 53–58
V_{O_2}resp, weaning failure and, 46–47
Volume challenge, in post-cardiac surgery patients, 164–171

Weaning
difficult, strategies/techniques for, 52–53
failure, etiology/pathophysiology of, 39–47
partial support, 55–57
reduction of duration of mechanical ventilation and, 47–52
spontaneous breathing, initial trial of, 51–52
T-piece, 53, 55
tracheal gas insufflation for, 57